Analysts think ZNTL stock price could increase by 74%
Feb 13, 2026, 12:25 PM
16.03%
What does ZNTL do
Zentalis Pharmaceuticals, a San Diego-based clinical-stage biopharmaceutical company, develops novel small molecule therapeutics for cancer, including WEE1 inhibitor azenosertib and BCL-2 inhibitor ZN-d5. The company went public on April 3, 2020, and employs 168 people.
7 analysts think ZNTL stock price will increase by 74.36%. The current median analyst target is $4.08 compared to a current stock price of $2.34. The lowest analysts target is $2.02 and the highest analyst target is $9.45.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.